DMCRN-02-001: Assessing Pediatric Endpoints in DM1 (ASPIRE-DM1)

Virginia Commonwealth University (VCU)

Status: Enrolling

Conditions: CDM; Congenital Myotonic Dystrophy

Study type: Observational

Funder types: Other

Identifiers

NCT05224778

HM20023386

Details and patient eligibility

About

The overall goal of the study is to establish valid clinical endpoint assessments for children with congenital myotonic dystrophy type 1 and develop biomarkers for the condition.

Full description

Myotonic dystrophy type-1 (DM1) is an autosomal dominant disorder caused by a toxic CTG repeat expansion in the 3'UTR of the DMPK gene. DM1 is the most common adult-onset muscular dystrophy, with an overall prevalence of 1:8000. In approximately 10-20% of individuals with DM1, the onset of symptoms occurs at birth, which is known as congenital myotonic dystrophy (CDM).

Previous studies have enrolled a very limited number of children with CDM.

The rationale for this study is to include a larger population of patients with CDM in order to determine developmental milestones, measures of physical and cognitive function and quality of life, and correlate functional outcome measures with potential biomarkers in CDM .

Enrollment: 50 estimated patients

Sex: All

Ages: Under 59 months old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age neonate to 3 years 11 months at enrollment.
• A diagnosis of CDM, which is defined as children having symptoms of myotonic dystrophy in the newborn period (<30 days), such as hypotonia, feeding or respiratory difficulty, requiring hospitalization to a ward or to the neonatal intensive care unit for more than 72 hours; and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4>1,500).
• Guardian is willing and able to sign consent and follow study procedures

Exclusion criteria

• Any other non-DM1 illness that would interfere with the ability or results of the study in the opinion of the site investigator
• Significant trauma within one month
• Internal metal or devices (exclusion for DEXA component)
• History of bleeding disorder or platelet count <50,000
• History of reaction to local anesthetic

Trial design

50 participants in 1 patient group

Congenital Myotonic Dystrophy (CDM)

Description:

CDM group includes those aged neonate to 3 years, 11 months at enrollment. Individuals must have a diagnosis of CDM, which is defined as children having symptoms of myotonic dystrophy in the newborn period (\<30 days), such as hypotonia, feeding or respiratory difficulty, requiring hospitalization to a ward or to the neonatal intensive care unit for more than 72 hours; and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4\>1,500).